PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

PHAS was delisted on the 2nd of November, 2022.

Back to rankings

15 hedge funds and large institutions have $21.2M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
15
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$10.4M
2
+$3.39M
3
+$2.58M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.01M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$592K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
1
$10.4M
2
$3.39M
3
$2.58M
4
$2.01M
5
$592K
6
$544K
7
$411K
8
$351K
9
$309K
10
$286K
11
$167K
12
$96K
13
$79K
14
$6K
15
$1K